cellmid-4

Lyramid: Inflammatory and Fibrotic Diseases


Cellmid holds has the most comprehensive global patent portfolio around the use of anti-MK agents for treating inflammatory and other diseases. The company has a pre-clinical program in place (CAB101) to evaluate novel anti-MK antibodies in the treatment of conditions such as chronic kidney disease. 

Studies have shown that MK is involved in pro-inflammatory processes and induces inflammation via several mechanisms. Cellmid’s CAB101 anti-MK antibody is designed to sequester circulating MK in the body, inhibiting its action and preventing it from promoting and perpetuating unwanted inflammation and associated fibrotic processes.  

Cellmid’s CAB101 anti-MK antibody therapy aims to fulfil a massive unmet medical need for safe and effective anti-inflammatory and anti-fibrotic compounds. Therapeutic antibodies  have proven safety profiles and are suitable for long term use making Cellmid’s CAB101 anti-MK antibody therapy a feasible drug candidate in several disease indications. 

An area of significant unmet need in the community is in chronic kidney disease (CKD), with an estimated 10-14% of adults in the developed world having some evidence of CKD.  In the US, prevalence of CKD in the adult population equates to ~20 million individuals.  CKD is thought to be responsible for up to one million deaths per annum worldwide.  This level of disease in the population creates an enormous financial burden particularly on the public healthcare system.  In the US, the treatment of CKD and dialysis patients is responsible for 20% of Medicare expenditure, which is representative of 3% of the total federal budget.  

CKD incidence is associated with poor diet and lifestyle and increases with age. As there is a large aging population bubble in the western world accompanied by increasing obesity rates, the incidence of CKD is predicted to rise.   The global market for therapeutics for Renal and Kidney disease is predicted to reach US$73 billion by 2017.

 

 

Another indication that anti-MK therapy may be useful is in liver disease, in particular Non-Alcoholic steatohepatitis (NASH). NASH has been described as ‘the next global epidemic’ (Defined Health 2015), and its incidence is associated with poor diet and lifestyle.  In the US 30% of adults (80 million individuals) and 10% of children are thought to have liver disease, and 10-30% of these have progressed to NASH, with 25-40% of NASH patients at risk of developing advanced hepatic fibrosis.   

Despite the large societal and healthcare burden that NASH represents, there are no FDA approved drugs for the condition making this an area of extreme unmet need.  It has been forecasted that the market for NASH treatments could reach US$35-40 billion by 2025 (Defined Health 2015).